Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 164Lung Neoplasms 61Small Cell Lung Carcinoma 24Neoplasms 10NSCLC 9Mesothelioma, Malignant 9Breast Neoplasms 8Pancreatic Neoplasms 7Ovarian Neoplasms 7Melanoma 6Head and Neck Neoplasms 6Colorectal Neoplasms 6Esophageal Neoplasms 5Stomach Neoplasms 4Neoplasm Metastasis 4Mesothelioma 4Kidney Neoplasms 4Brain Neoplasms 4Sarcoma 3Pleural Effusion, Malignant 3Liver Neoplasms 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Carcinoma 3Adenocarcinoma of Lung 3Uterine Cervical Neoplasms 2Thymus Neoplasms 2Thymoma 2Small Cell Lung Cancer Limited Stage 2Skin Neoplasms 2

Interventions

toripalimab 1anlotinib 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Non Small Cell Lung Cancer Recurrent × Drug Therapy × Thoracic × Clear all
NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Non Small Cell Lung Cancer Recurrent

Data powered by HemOnc (CC BY 4.0) Colophon âš¡